Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The research in our group focuses on target identification and validation in a spectrum of human diseases including benign and malignant soft tissue tumours or hematological malignancies affecting the skeleton such as multiple myeloma, and inflammatory conditions including endometriosis, cardiovascular disease, or autoimmune diseases.

Lead image 1

The use of chemical, molecular and structural biology, combined with single-cell imaging and sequencing technologies provides a platform for us to understand human biology and is a major focus of the group. These approaches are currently applied to identify and validate epigenetic or metabolic mechanisms in stem cell biology, as well as chronic inflammatory, malignant and benign proliferative diseases.

In particular, our aim is to identify possible novel therapeutic intervention points in malignant such as bone and soft tissue cancers like sarcoma or in multiple myeloma, and in inflammatory or fibrotic conditions including arthritis and ankylosing spondylitis, cardiovascular disease, endometriosis or uterine fibroids. These goals are pursued in highly collaborative projects, such as the Oxford-Bayer Alliance in Women's Health and the Oxford Centre for Translational Myeloma Research.

Chemical tools such as selective and cell-active inhibitors are important in understanding biological systems. We pursue the development and characterisation of chemical tools for epigenetic biology within the Epigenetic Probe Project, a public-private partnership between the Structural Genomics Consortium (SGC) and several academic, private and patient organisations. 

Related research themes